Virbac Overview

  • Year Founded
  • 1968

Year Founded

  • Status
  • Public

  • Employees
  • 50

Employees

  • Stock Symbol
  • VIRP

Stock Symbol

  • Investments
  • 16

  • Share Price
  • $393.02
  • (As of Monday Closing)

Virbac General Information

Description

Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 13e rue LID
  • BP 27
  • 06511 Carros
  • France
+33 04
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
PAR
Corporate Office
  • 13e rue LID
  • BP 27
  • 06511 Carros
  • France
+33 04

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Virbac Stock Performance

As of 16-Nov-2026, Virbac’s stock price is $393.02. Its current market cap is $3.29B with 8.38M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$393.02 $391.71 $340.82 - $458.83 $3.29B 8.38M 5.39K $21.70

Virbac Financials Summary

As of 30-Jun-2026, Virbac has a trailing 12-month revenue of $1.74B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,371,982 3,748,479 3,014,921 3,270,286
Revenue 1,743,194 1,652,165 1,512,102 1,349,241
EBITDA 340,923 317,850 291,903 240,037
Net Income 181,805 170,201 157,218 131,254
Total Assets 2,375,443 2,248,417 1,923,520 1,609,164
Total Debt 408,647 339,266 319,470 132,770
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Virbac Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Virbac‘s full profile, request access.

Request a free trial

Virbac Patents

Virbac Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3173466-A1 Veterinary oral medicinal composition Pending 30-Apr-2025
FR-3173464-A3 Veterinary oral medicinal composition Pending 26-Mar-2025
FR-3173465-A1 Veterinary oral medicinal composition Pending 26-Mar-2025
WO-2026202141-A1 Veterinary oral medicinal composition Pending 26-Mar-2025
FR-3169909-A1 An undirected, constrained, and accelerated process for modifying pathogenic bacterial strains for the preparation of live attenuated vaccines and resulting strains Pending 12-Dec-2024 A61K39/092
To view Virbac’s complete patent history, request access »

Virbac Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Virbac Investments & Acquisitions (16)

Virbac’s most recent deal was a Corporate Asset Purchase with Norbrook Laboratories (Feline Hyperthyroidism Drug) for . The deal was made on 16-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Norbrook Laboratories (Feline Hyperthyroidism Drug) 16-Dec-2025 Corporate Asset Purchase Buildings and Property
Mopsan Veterinary Products 02-Dec-2024 Merger/Acquisition Distributors (Healthcare)
Globion 21-Jun-2024 Secondary Transaction - Private Other Consumer Non-Durables
Sasaeah 01-Apr-2024 Merger/Acquisition Other Consumer Non-Durables
Globion 01-Nov-2023 Merger/Acquisition Other Consumer Non-Durables
You’re viewing 5 of 16 investments and acquisitions. Get the full list »

Virbac ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

17.79 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Virbac’s complete esg history, request access »

Virbac Exits (1)

Virbac’s most recent exit was on 02-Jan-2015 from Eli Lilly (Rights and Titles of Sentinel Flavor Tabs and Sentinel Spectrum). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Eli Lilly (Rights and Titles of Sentinel Flavor Tabs and Sentinel Spectrum) 02-Jan-2015 Completed
To view Virbac’s complete exits history, request access »

Virbac Affiliates

Subsidiaries (13)

Name Industry Location Year Founded
Sasaeah Shinagawa, Japan 2020
Norbrook Laboratories (Feline Hyperthyroidism Drug) Newry, United Kingdom 2016
Globion Secunderabad, India 2005
Ivet (Internet Retail) Parkville, MO 2002
Mopsan Veterinary Products Atasehir, Turkey 1993
You’re viewing 5 of 13 affiliates. Get the full list.  »

Virbac FAQs

  • When was Virbac founded?

    Virbac was founded in 1968.

  • Where is Virbac headquartered?

    Virbac is headquartered in Carros, France.

  • What is the size of Virbac?

    Virbac has 50 total employees.

  • What industry is Virbac in?

    Virbac’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Virbac a private or public company?

    Virbac is a Public company.

  • What is Virbac’s stock symbol?

    The ticker symbol for Virbac is VIRP.

  • What is the current stock price of Virbac?

    As of 16-Nov-2026 the stock price of Virbac is $393.02.

  • What is the current market cap of Virbac?

    The current market capitalization of Virbac is $3.29B.

  • What is Virbac’s current revenue?

    The trailing twelve month revenue for Virbac is $1.74B.

  • What is Virbac’s annual earnings per share (EPS)?

    Virbac’s EPS for 12 months was $21.70.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process